Founders Capital Management (Connecticut)’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.23M | Buy |
8,385
+182
| +2% | +$124K | 0.78% | 26 |
|
|
2026
Q1 | $6.34M | Hold |
8,203
| – | – | 1.04% | 22 |
|
|
2025
Q4 | $6.33M | Sell |
8,203
-74
| -0.9% | -$50.3K | 0.94% | 22 |
|
|
2025
Q3 | $4.65M | Buy |
8,277
+3
| +0% | +$1.7K | 0.73% | 26 |
|
|
2025
Q2 | $4.34M | Buy |
8,274
+538
| +7% | +$300K | 0.74% | 25 |
|
|
2025
Q1 | $4.91M | Sell |
7,736
-232
| -3% | -$160K | 0.9% | 25 |
|
|
2024
Q4 | $5.68M | Buy |
7,968
+236
| +3% | +$198K | 1% | 24 |
|
|
2024
Q3 | $8.13M | Sell |
7,732
-53
| -0.7% | -$59K | 1.41% | 19 |
|
|
2024
Q2 | $8.18M | Sell |
7,785
-54
| -0.7% | -$52.3K | 1.47% | 19 |
|
|
2024
Q1 | $7.54M | Hold |
7,839
| – | – | 1.4% | 20 |
|
|
2023
Q4 | $6.88M | Sell |
7,839
-98
| -1% | -$80.7K | 1.41% | 21 |
|
|
2023
Q3 | $6.53M | Sell |
7,937
-95
| -1% | -$74.7K | 1.48% | 20 |
|
|
2023
Q2 | $5.77M | Sell |
8,032
-136
| -2% | -$105K | 1.29% | 22 |
|
|
2023
Q1 | $6.71M | Sell |
8,168
-122
| -1% | -$92K | 1.67% | 19 |
|
|
2022
Q4 | $5.98M | Sell |
8,290
-215
| -3% | -$159K | 1.61% | 21 |
|
|
2022
Q3 | $5.86M | Sell |
8,505
-106
| -1% | -$66.7K | 1.64% | 21 |
|
|
2022
Q2 | $5.09M | Buy |
8,611
+24
| +0.3% | +$15.6K | 1.3% | 21 |
|
|
2022
Q1 | $6M | Buy |
8,587
+84
| +1% | +$53.1K | 1.29% | 21 |
|
|
2021
Q4 | $5.37M | Sell |
8,503
-296
| -3% | -$182K | 1.16% | 20 |
|
|
2021
Q3 | $5.33M | Sell |
8,799
-122
| -1% | -$75.7K | 1.35% | 20 |
|
|
2021
Q2 | $4.98M | Buy |
8,921
+5,001
| +128% | +$2.53M | 1.2% | 21 |
|
|
2021
Q1 | $1.85M | Buy |
3,920
+3,343
| +579% | +$1.63M | 0.47% | 39 |
|
|
2020
Q4 | $279K | Hold |
577
| – | – | 0.08% | 62 |
|
|
2020
Q3 | $323K | Hold |
577
| – | – | 0.1% | 55 |
|
|
2020
Q2 | $360K | Hold |
577
| – | – | 0.12% | 51 |
|
|
2020
Q1 | $282K | Hold |
577
| – | – | 0.11% | 50 |
|
|
2019
Q4 | $217K | Hold |
577
| – | – | 0.07% | 55 |
|
|
2019
Q3 | $163K | Hold |
577
| – | – | 0.06% | 55 |
|
|
2019
Q2 | $181K | Hold |
577
| – | – | 0.06% | 57 |
|
|
2019
Q1 | $237K | Hold |
577
| – | – | 0.09% | 54 |
|
|
2018
Q4 | $216K | Hold |
577
| – | – | 0.09% | 49 |
|
|
2018
Q3 | $226K | Buy |
+577
| New | +$220K | 0.09% | 50 |
|
|
2018
Q1 | – | Sell |
-577
| Closed | -$217K | – | 55 |
|
|
2017
Q4 | $217K | Hold |
577
| – | – | 0.1% | 51 |
|
|
2017
Q3 | $258K | Sell |
577
-100
| -15% | -$47.6K | 0.12% | 50 |
|
|
2017
Q2 | $333K | Hold |
677
| – | – | 0.17% | 40 |
|
|
2017
Q1 | $262K | Hold |
677
| – | – | 0.13% | 45 |
|
|
2016
Q4 | $249K | Hold |
677
| – | – | 0.13% | 46 |
|
|
2016
Q3 | $272K | Hold |
677
| – | – | 0.15% | 44 |
|
|
2016
Q2 | $236K | Hold |
677
| – | – | 0.13% | 46 |
|
|
2016
Q1 | $244K | Hold |
677
| – | – | 0.14% | 46 |
|
|
2015
Q4 | $368K | Hold |
677
| – | – | 0.22% | 38 |
|
|
2015
Q3 | $315K | Hold |
677
| – | – | 0.2% | 43 |
|
|
2015
Q2 | $345K | Hold |
677
| – | – | 0.21% | 43 |
|
|
2015
Q1 | $306K | Hold |
677
| – | – | 0.18% | 46 |
|
|
2014
Q4 | $278K | Hold |
677
| – | – | 0.17% | 42 |
|
|
2014
Q3 | $244K | Buy |
+677
| New | +$227K | 0.16% | 42 |
|
|
2014
Q2 | – | Sell |
-677
| Closed | -$203K | – | 46 |
|
|
2014
Q1 | $203K | Buy |
+677
| New | +$209K | 0.16% | 39 |
|
Other funds holding REGN
Founders Capital Management (Connecticut)'s REGN Position: Q2 2026 in Review
Founders Capital Management (Connecticut) increased its Regeneron Pharmaceuticals (REGN) stake by 2.2% in Q2 2026, buying an estimated $124K and bringing the position to 8,385 shares worth $5.23M. The position accounts for 0.78% of the portfolio, ranked #26.
Founders Capital Management (Connecticut) first reported a position in REGN in Q1 2014 and has held it in 47 quarters since. The position peaked at $8.18M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Founders Capital Management (Connecticut) held 8,385 shares of Regeneron Pharmaceuticals worth $5.23M as of Q2 2026.
- Founders Capital Management (Connecticut) bought 182 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $124K.
- Regeneron Pharmaceuticals made up 0.78% of Founders Capital Management (Connecticut)'s portfolio in Q2 2026, its #26 holding.
- Founders Capital Management (Connecticut) first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 47 quarters since.
- Founders Capital Management (Connecticut)'s Regeneron Pharmaceuticals position peaked at $8.18M in Q2 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Founders Capital Management (Connecticut)'s 13F filing for Q2 2026, filed 20 Jul 2026.